CooperVision MiSight 1 day Contact Lenses (IMAGE)
Caption
CooperVision, a world leader in myopia control and management for children, has announced new seven-year findings from its pivotal MiSight® 1 day contact lens clinical trial. Twelve months following treatment cessation, mean axial elongation data indicate no evidence of rebound effect, meaning the myopia control gains are retained.
Credit
CooperVision
Usage Restrictions
None
License
Original content